FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, namely to conjugates of oxyntomodulin with immunoglobulin Fc-region, and can be used in medicine for treating obesity. Conjugate, capable of activating receptor CLP-1 (glucagon-like peptide-1), and glucagon receptor, are obtained, which contains derivative of oxyntomodulin with SEQ ID NO: 23, 24, 25, 32, 33 or 34, covalently bound with Fc-region of immunoglobulin by polyethylene glycol.
EFFECT: invention enables to obtain conjugate of oxyntomodulin, which reduces food consumption, suppresses gastric emptying and promotes lipolysis without side effects in contrast to native oxyntomodulin and also shows excellent receptor-activating effects and long-term stability as compared to native oxyntomodulin.
18 cl, 13 dwg, 4 tbl, 18 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CONJUGATE CONTAINING OXINTOMODULIN AND IMMUNOGLOBULIN FRAGMENT, AND ITS APPLICATION | 2012 |
|
RU2733544C2 |
| COMPOSITION FOR HYPERLIPIDEMIA TREATMENT CONTAINING OXYNTOMODULIN DERIVATIVE | 2013 |
|
RU2642267C2 |
| COMPOSITION FOR TREATING HYPERLIPIDEMIA CONTAINING AN OXYNTOMODULIN DERIVATIVE | 2013 |
|
RU2768853C1 |
| METHOD OF CONTROLLING CONDITIONS FOR SITE-SPECIFIC BINDING OF POLYPEPTIDE AND NON-PEPTIDE POLYMER | 2010 |
|
RU2495881C2 |
| COMPOSITION FOR TREATING DIABETES, CONTAINING LONG-ACTING INSULIN CONJUGATE AND LONG-ACTING INSULINOTROPIC PEPTIDE CONJUGATE | 2012 |
|
RU2606840C2 |
| NEW METHOD FOR OBTAINING LONG-ACTING DRUG CONJUGATE BY PRODUCING INTERMEDIATE | 2019 |
|
RU2805873C2 |
| IMPROVED METHOD FOR HIGH-YIELD PRODUCTION OF PHYSIOLOGICALLY ACTIVE POLYPEPTIDE CONJUGATE | 2014 |
|
RU2677796C9 |
| DERIVATIVES OF BLOOD COAGULATION FACTORS VII AND VIIA, CONJUGATES AND COMPLEXES CONTAINING THEM AND THEIR APPLICATION | 2012 |
|
RU2620072C2 |
| NOVEL INSULIN ANALOGUE AND USE THEREOF | 2014 |
|
RU2676729C2 |
| NOVEL OXYNTOMODULIN DERIVATIVES AND A PHARMACEUTICAL COMPOSITION CONTAINING THEM FOR TREATING OBESITY | 2012 |
|
RU2739209C2 |
